Loading...
XNAS
NEUP
Market cap18mUSD
Oct 08, Last price  
3.35USD
1D
-2.05%
1Q
-5.37%
Name

Bionomics Ltd

Chart & performance

D1W1MN
XNAS:NEUP chart
P/E
—
P/S
22.15
EPS
—
Div yield, %
—
Shrs. gr., 5y
-47.74%
Rev. gr., 5y
25.10%
Revenues
1m
-92.50%
2,913,8512,543,9233,402,0681,152,4581,494,11518,022,1675,084,5335,214,9224,130,9012,757,2593,820,0002,678,39432,0620383,15620,0000015,649,4481,174,165
Net income
-13m
L+3,539.28%
-5,538,221-6,980,905-9,999,889-3,209,609-9,127,2343,019,014-13,000,203-12,403,110-5,186,744-18,427,652-9,670,000-6,771,657-4,891,117-6,534,408-31,624,469-31,850,000-32,181,704-23,193,321-369,632-13,451,931
CFO
-12.35b
L
-5,829,441-5,543,957-4,328,943-6,916,365-7,895,000-2,945,800-10,439,193-12,913,2134,936,118-15,359,554-1,439,842-15,024,456-10,912,614-2,681,961-5,664,125-21,753,190-9,846,030-14,681,00077,229,000-12,353,074,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Bionomics Limited, an Australian clinical-stage biopharmaceutical company founded in 1996 and based in Eastwood, focuses on identifying and developing innovative drug candidates to address central nervous system conditions and various cancers. A significant experimental medicine in their pipeline is BNC210, a negative allosteric modulator targeting the a7 nicotinic acetylcholine receptor. This compound is currently undergoing a Phase 2 clinical trial for social anxiety disorder and a Phase 2b study for post-traumatic stress disorder (PTSD). The company's portfolio also includes BNC101, a monoclonal antibody designed to combat cancer stem cells, which has successfully completed its Phase 1 clinical evaluation. Additionally, Bionomics is advancing BNC105, currently in a Phase 2 clinical trial for refractory colorectal cancer and a Phase 1 trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
URL
https://www.bionomics.com.au/
IPO date
Dec 21, 1999
Employees
140
Domiciled in
AU
Incorporated in
AU
Headquarters & legal address
c/o BIONOMICS LIMITED, 31 Dalgleish Street
Thebarton, SA 5031
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062023‑062022‑062021‑062020‑062019‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT